Oxathiazin Compounds Inhibit GAPDH via Isethionic Acid Metabolite
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to safely and specifically modulate the activity of Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which is involved in various diseases including cancer and neurodegenerative disorders, due to its complex and diverse functional roles in cellular processes.
Innovation Solution
Administration of compounds that hydrolyze or metabolize in vivo to form isethionic acid hydroxymethylamide, which inhibits GAPDH activity, reducing its enzymatic function and associated disease-related processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GAPDH is inhibited to treat cancer and neurodegenerative disorders, then disease-related processes are reduced, but cellular energy metabolism is disrupted
Solution Approach 1:
The patent applies selective inhibition by designing compounds that specifically target GAPDH in certain cellular contexts. The inhibitor preferentially affects GAPDH activity in tumor cells or neurons where it drives pathology, while sparing GAPDH function in normal tissues that rely on it for energy metabolism, thus achieving local therapeutic effect without global metabolic disruption
Solution Approach 2:
The patent modulates GAPDH activity by changing its functional state through specific chemical inhibition rather than complete elimination. The inhibitor binds to GAPDH and alters its catalytic parameters, reducing its activity to a controlled level that prevents disease progression while maintaining sufficient metabolic function in normal cells
2Productivity
If GAPDH activity is reduced to inhibit tumor growth, then cancer progression is slowed, but ATP production decreases
Solution Approach 1:
The patent applies partial inhibition of GAPDH activity rather than complete shutdown. The inhibitor reduces GAPDH activity to a degree that is sufficient to slow tumor growth and prevent cancer progression, but not so severe as to completely eliminate ATP production. This partial action allows the tumor to be restrained while maintaining minimal energy metabolism
Solution Approach 2:
The patent exploits the fact that tumor cells have high GAPDH activity as a vulnerability. By selectively inhibiting GAPDH in tumor cells, the therapy converts their excessive metabolic activity from a survival advantage into a therapeutic target. The high ATP consumption of tumor cells makes them more sensitive to GAPDH inhibition than normal cells, turning their metabolic profile against them
3Reliability
If GAPDH is inhibited to prevent neurodegeneration, then neuronal damage is reduced, but cellular stress increases
Solution Approach 1:
The patent uses a chemical intermediary substance that selectively interferes with GAPDH function in neurons. The inhibitor acts as a mediator that blocks the harmful activities of GAPDH in neurodegenerative conditions (such as abnormal protein aggregation and oxidative stress) while allowing normal cellular functions to continue, thus protecting neurons without causing widespread cellular stress
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively inhibits GAPDH activity in cells, reducing ATP production, increasing reactive species in tumors, and preventing disease symptoms associated with GAPDH, while minimizing impact on normal cells, thus offering a broad therapeutic tool for various medical conditions.
Implementation Method 1
compounds that hydrolyze or metabolize in vivo to form isethionic acid hydroxymethylamide
Data Source
AI summary
A method of inhibiting GAPDH with certain oxathiazin-like compounds and/or related compounds.